TD Cowen raised the firm’s price target on Leidos to $166 from $155 and keeps a Buy rating on the shares. The firm said despite a VA funding delay in H2, hiked 2024 guide has opportunity thanks to Q2’s medical exam spike; a tough exam compare next year is apt to be outweighed by improvement elsewhere.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LDOS: